Antidepressants for the treatment of chronic pain.

Department of Psychiatry, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
Drugs (Impact Factor: 4.13). 02/2008; 68(18):2611-32. DOI: 10.2165/0003495-200868180-00007
Source: PubMed

ABSTRACT Chronic pain represents one of the most important public health problems and, in addition to classical analgesics, antidepressants are an essential part of the therapeutic strategy. This article reviews available evidence on the efficacy and safety of antidepressants in major chronic pain conditions; namely, neuropathic pain, headaches, low back pain, fibromyalgia, irritable bowel syndrome (IBS) and cancer pain. Studies, reviews and meta-analyses published from 1991 to March 2008 were retrieved through MEDLINE, PsycINFO and the Cochrane database using numerous key words for pain and antidepressants. In summary, evidence supports the use of tricyclic antidepressants in neuropathic pain, headaches, low back pain, fibromyalgia and IBS. The efficacy of the newer serotonin and norepinephrine reuptake inhibitors is less supported by evidence, but can be recommended in neuropathic pain, migraines and fibromyalgia. To date, evidence does not support an analgesic effect of serotonin reuptake inhibitors, but beneficial effects on well-being were reported in several chronic pain conditions. These results are discussed in the light of current insights in the neurobiology of pain, the reciprocal relationship between pain and depression, and future developments in this field of research.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Potentially inappropriate medication (PIM) use has been associated with an increase in adverse drug events, hospitalization and mortality. This study investigated the prevalence and factors associated with PIM use in patients presenting to a medical oncology outpatient clinic. Materials and Methods Consecutive patients (n = 385) aged ≥ 70 years referred to a medical oncology outpatient clinic between January 2009 and July 2010 completed a structured data collection instrument. The instrument assessed medication use, diagnoses, self-reported falls in the previous six months, pain (10-point visual analog scale [VAS]) and distress (10-point VAS). Frailty was defined using exhaustion, weight loss, Karnofsky Performance Scale, instrumental activities of daily living and physical function. PIM use was defined by the Beers Criteria. Logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for factors associated with PIM use. Results In total, 26.5% (n = 102) of the sample used ≥ 1 PIM. The five most prevalent classes of PIMs were benzodiazepines (n = 34, 8.8%), tricyclic antidepressants (n = 16, 4.2%), alpha-adrenoreceptor antagonists (prazosin) (n = 15, 3.9%), propulsives (metoclopramide) (n = 15, 3.9%) and non-steroidal anti-inflammatory drugs (n = 14, 3.6%). In multivariate analyses, PIM use was associated with age 75–79 years (OR 1.83; 95%CI 1.02–3.26) compared to age 70–74 years, using ≥ 5 medications (OR 4.10; 95%CI 2.26–7.44) compared to < 5 medications and being frail (OR 3.05; 95%CI 1.18–7.87) compared to being robust. Conclusion More than one quarter of older people with cancer used one or more PIMs, and this was associated with being frail compared to being robust.
    Journal of Geriatric Oncology 10/2014; · 1.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: In chronic pain disorders, galanin (GAL) is able to either facilitate or inhibit nociception in the spinal cord but the contribution of supraspinal galanin to pain signalling is mostly unknown. The dorsomedial nucleus of the hypothalamus (DMH) is rich in galanin receptors (GALR) and is involved in behavioural hyperalgesia. In this study, we evaluated the contribution of supraspinal GAL to behavioural hyperalgesia in experimental monoarthritis. Methods: (PWL) was assessed before and after DMH administration of exogenous GAL, a non-specific GALR antagonist (M40), a specific GALR1 agonist (M617) and a specific GALR2 antagonist (M871). Additionally, the analysis of c-Fos expression after GAL injection in the DMH was used to investigate the potential involvement of brainstem pain control centres. Finally, electrophysiological recordings were performed to evaluate whether pronociceptive On-or antinociceptive Off-like cells in the rostral ventromedial medulla (RVM) relay the effect of GAL. Results: Exogenous GAL in the DMH decreased PWL in ARTH and SHAM animals, an effect that was mimicked by a GALR1 agonist (M617). In SHAM animals, an unselective GALR antagonist (M40) increased PWL, while a GALR2 antagonist (M871) decreased PWL. M40 or M871 failed to influence PWL in ARTH animals. Exogenous GAL increased c-Fos expression in the RVM and dorsal raphe nucleus (DRN), with effects being more prominent in SHAM than ARTH animals. Exogenous GAL failed to influence activity of RVM On-or Off-like cells of SHAM and ARTH animals. Conclusions: Overall, exogenous GAL in the DMH had a pronociceptive effect that is mediated by GALR1 in healthy and arthritic animals and is associated with alterations of c-Fos expression in RVM and DRN that are serotonergic brainstem nuclei known to be involved in the regulation of pain. Copyright: ß 2014 Amorim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All data (excel) files are available from the University of Minho Repository ( = en). Funding: SFRH/BD/90374/2012. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist.
    PLoS ONE 11/2014; 9(11):e113077. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of chronic pain arising from deep tissues is currently inadequate and there is need for new pharmacological agents to provide analgesia. The endogenous paracrine hormone/neurotransmitter oxytocin is intimately involved in the modulation of multiple physiological and psychological functions. Recent experiments have given clear evidence for a role of oxytocin in the modulation of nociception. The present article reviews the existent human and basic science data related to the direct and indirect effects of oxytocin on pain. Due to its analgesic, anxiolytic, antidepressant and other central nervous system effects, there is strong evidence that oxytocin and other drugs acting through the oxytocin receptor could act as multifunctional analgesics with unique therapeutic value.
    Current Pharmaceutical Design 10/2014; · 3.29 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014